<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926027</url>
  </required_header>
  <id_info>
    <org_study_id>21733-01</org_study_id>
    <nct_id>NCT02926027</nct_id>
  </id_info>
  <brief_title>Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy</brief_title>
  <acronym>EVAPORATE</acronym>
  <official_title>Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons With Elevated Triglycerides (200-499) on Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intermountain Research and Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons with Elevated&#xD;
      Triglycerides (200-499) on Statin Therapy. The study is to determine progression rates of low&#xD;
      attenuation plaque under influence of Vascepa as compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Residual cardiovascular (CV) risk remains in dyslipidemic patients despite intensive statin&#xD;
      therapy, underscoring the need for additional intervention. Eicosapentaenoic acid (EPA), an&#xD;
      omega-3 polyunsaturated fatty acid, is incorporated into membrane phospholipids and&#xD;
      atherosclerotic plaques and exerts beneficial effects on the pathophysiologic cascade from&#xD;
      onset of plaque formation through rupture. EPA also improves atherogenic dyslipidemia&#xD;
      characterized by reduction of triglycerides without raising low-density lipoprotein&#xD;
      cholesterol. All of this data supports the biologic plausibility of EPA as an&#xD;
      anti-atherosclerotic agent. The goal of this study is to evaluate whether treatment with&#xD;
      Vascepa (4 grams) results in a greater change from baseline in low attenuation plaque than&#xD;
      placebo in subjects with elevated triglycerides (200-499 mg/dl).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Actual">August 15, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points</measure>
    <time_frame>18 months</time_frame>
    <description>low attenuation plaque volume change from baseline to 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Composition of Non-calcified Coronary Atherosclerotic Plaque (NCP)</measure>
    <time_frame>18 months</time_frame>
    <description>the measure is reported as volume of non-calcified plaque, as the secondary measure has been reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Active subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vascepa (4 gm/day), oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo subject</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vascepa</intervention_name>
    <description>Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.</description>
    <arm_group_label>Active subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo subject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elevated triglycerides (fasting value between 200-499 mg/dl) at qualifying or baseline&#xD;
             visit.&#xD;
&#xD;
          -  LDL-C ≤115 mg/dL on appropriate statin therapy&#xD;
&#xD;
          -  LDL-C &gt;40 mg/dL&#xD;
&#xD;
          -  Stable diet and exercise, as defined as the same pattern for the previous 4 weeks&#xD;
&#xD;
          -  Stable treatment with a statin+/- ezetimibe for at least 4 weeks&#xD;
&#xD;
          -  Patients with at least 1 angiographic stenosis with at least 20% narrowing by coronary&#xD;
             computed tomography angiography (CTA).&#xD;
&#xD;
          -  Willingness to be on birth control for women of childbearing age or established&#xD;
             post-menopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A contraindication to fish or fish oils including: known hypersensitivity to drug or&#xD;
             fish.&#xD;
&#xD;
          -  Any unstable medical, psychiatric or substance abuse disorder that in the opinion of&#xD;
             the investigator or principal investigator is likely to affect the subject's ability&#xD;
             to complete the study or precludes the subject's participation in the study.&#xD;
&#xD;
          -  Non-study lipid altering medications or supplements (ie - Niacin, PCSK9, fibrates,&#xD;
             bile acid Sequestrants, dietary fish oil supplement capsules, orlistat [OTC (Alli®) as&#xD;
             well as Rx (Xenical®)] or other drugs used for weight loss).&#xD;
&#xD;
          -  Stable (same daily dose for the last 4 weeks) on medications that can affect lipids&#xD;
             (retinoids, hormones, steroids, HIV medications, chemotherapy, thyroid medications).&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Uncontrolled hypertension (SBP≥ 180 mmHg or DBP≥100 mmHg)&#xD;
&#xD;
          -  History of known myocardial infarction, stroke or life-threatening arrhythmia within&#xD;
             the prior six months.&#xD;
&#xD;
          -  NYHA Class III- IV heart failure&#xD;
&#xD;
          -  History of malignancy within the last 5 years (other than skin cancer) or evidence of&#xD;
             active cancer which would require concomitant cancer chemotherapy.&#xD;
&#xD;
          -  Serum creatinine &gt; 1.4 mg/dl&#xD;
&#xD;
          -  Drug or alcohol abuse, or current intake of more than 14 ounces of alcohol per week&#xD;
             for men and 10 ounces for women&#xD;
&#xD;
          -  Concurrent enrollment in another placebo-controlled trial or within 30 days of&#xD;
             finishing another trial&#xD;
&#xD;
          -  Partial ileal bypass or known gastrointestinal disease limiting drug absorption&#xD;
&#xD;
          -  History of hypertensive encephalopathy or cerebrovascular accident&#xD;
&#xD;
          -  Hematological or biochemical values at screening outside the reference ranges&#xD;
             considered as clinically significant in the opinion of the investigator or PI&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Genetic mutations/polymorphisms having an effect on blood lipids&#xD;
&#xD;
          -  History of coronary artery bypass surgery&#xD;
&#xD;
          -  Allergy to contrast material&#xD;
&#xD;
          -  Allergy to beta-blocker in subjects with resting heart rate &gt;70 bpm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Budoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation (The Lundquist Institute)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center, Intermountain Heart Institute</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <results_first_submitted>July 2, 2021</results_first_submitted>
  <results_first_submitted_qc>October 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew J. Budoff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be tabulated and analysed. Study site will not share any of the subject identifiers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02926027/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Subjects</title>
          <description>Vascepa (4 gm/day), oral dose&#xD;
Vascepa: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Subject</title>
          <description>oral dose of placebo&#xD;
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Subjects</title>
          <description>Vascepa (4 gm/day), oral dose&#xD;
Vascepa: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Subject</title>
          <description>oral dose of placebo&#xD;
placebo: placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="8.9"/>
                    <measurement group_id="B2" value="58.3" spread="8.6"/>
                    <measurement group_id="B3" value="57.4" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points</title>
        <description>low attenuation plaque volume change from baseline to 18 months</description>
        <time_frame>18 months</time_frame>
        <population>completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Active Subjects</title>
            <description>Vascepa (4 gm/day), oral dose&#xD;
Vascepa: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Subject</title>
            <description>oral dose of placebo&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points</title>
          <description>low attenuation plaque volume change from baseline to 18 months</description>
          <population>completed study</population>
          <units>volume in mm cubed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.5"/>
                    <measurement group_id="O2" value="0.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Composition of Non-calcified Coronary Atherosclerotic Plaque (NCP)</title>
        <description>the measure is reported as volume of non-calcified plaque, as the secondary measure has been reported.</description>
        <time_frame>18 months</time_frame>
        <population>all participants finishing final CT angiogram</population>
        <group_list>
          <group group_id="O1">
            <title>Active Subjects</title>
            <description>Vascepa (4 gm/day), oral dose&#xD;
Vascepa: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Subject</title>
            <description>oral dose of placebo&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Composition of Non-calcified Coronary Atherosclerotic Plaque (NCP)</title>
          <description>the measure is reported as volume of non-calcified plaque, as the secondary measure has been reported.</description>
          <population>all participants finishing final CT angiogram</population>
          <units>MM CUBED</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.2"/>
                    <measurement group_id="O2" value="0.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 month follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Subjects</title>
          <description>Vascepa (4 gm/day), oral dose&#xD;
Vascepa: Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Subject</title>
          <description>oral dose of placebo&#xD;
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew Budoff</name_or_title>
      <organization>Lundquist Institute</organization>
      <phone>3102224107</phone>
      <email>mbudoff@lundquist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

